Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (124) clinical trials

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase

The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

Phase

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in ...

Phase

Multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosage, Phase 2a study comparing 3 dosages of LY3154207

Phase

NAVIGATE-AD is a 52 week (plus a 4 week follow up visit), double blind study where participants will be randomly assigned (like the flip of a coin) to receive either 1 of 2 doses of study drug (LY32022626) or a placebo (tablet containing no active ingredients, similar to a "sugar ...

Phase

NEUP11-AD2 is a 26 week (plus a 2 week Follow up Visit) double blind study where participants will be randomly assigned (like the flip of a coin) to receive either 1 of 3 doses of study drug (Piromelatine) or a placebo (tablet containing no active ingredients, similar to a sugar ...

Phase

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer’s disease.

Phase